Literature DB >> 1970363

Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats.

T H Lin1, J H Lin.   

Abstract

The brain uptake of a number of benzodiazepines with different lipophilic and protein binding characteristics was investigated in male Sprague-Dawley rats using the rapid intracarotid artery injection technique. When the compounds were administered as a solution in Ringer's buffer, pH 7.4, the uptake was in the order of [14C]diazepam greater than [14C]L-663,581 (anxiolytic agent) greater than [3H]L-364,718 (morphine analgesia potentiator) greater than [14C]L-365,260 (anxiolytic agent) and their extraction ratio values were 71.0 +/- 6.8, 65.0 +/- 12.0, 42.0 +/- 5.0 and 6.0 +/- 2.0%, respectively. The respective permeability-surface product values were 0.755 +/- 0.152, 0.647 +/- 0.180, 0.329 +/- 0.05 and 0.035 +/- 0.011 ml/min/g. The rank order of brain extraction did not correlate well with the drugs' lipophilicity determined by octanol-buffer partition coefficient. For example, L-365,260 had the highest octanol/buffer partition coefficient, but the lowest brain extraction. Plasma protein binding significantly decreased the uptake by the brain but to a lesser extent than that predicted from the unbound drug fraction in vitro, suggesting that drug binding to plasma protein did not limit the transport of drug through the blood-brain barrier. For one compound, L-364,718, the extraction ratio and permeability-surface product values were increased markedly in CC1(4)-induced hepatic injury. Other disease states, uranyl nitrate-induced renal failure and streptozotocin-induced diabetes, had no apparent effect on the uptake of the compounds tested. The effect of disease state on the brain uptake of drug appeared to be dependent on the type of disease and the type of drug studied.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970363

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.

Authors:  A Hoffman; Y Lomnicky; M H Luria; D Gilhar; M Friedman
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 2.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Exogenous cholecystokinin-8 reduces vagal efferent nerve activity in rats through CCK(A) receptors.

Authors:  V Bucinskaite; M Kurosawa; T Lundeberg
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep.

Authors:  R N Upton; G L Ludbrook; C Grant; A Martinez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

Review 5.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

6.  Measurement of drug-protein dissociation rates by high-performance affinity chromatography and peak profiling.

Authors:  John E Schiel; Corey M Ohnmacht; David S Hage
Journal:  Anal Chem       Date:  2009-06-01       Impact factor: 6.986

7.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.